Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2015 1
2016 1
2017 1
2019 1
2020 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, Zhang J, Loo J, Saglimbeni J, Abu-Akeel M, Zappasodi R, Riaz N, Smoragiewicz M, Kelley ZL, Basturk O; Australian Pancreatic Cancer Genome Initiative; Garvan Institute of Medical Research; Prince of Wales Hospital; Royal North Shore Hospital; University of Glasgow; St Vincent’s Hospital; QIMR Berghofer Medical Research Institute; University of Melbourne, Centre for Cancer Research; University of Queensland, Institute for Molecular Bioscience; Bankstown Hospital; Liverpool Hospital; Royal Prince Alfred Hospital, Chris O’Brien Lifehouse; Westmead Hospital; Fremantle Hospital; St John of God Healthcare; Royal Adelaide Hospital; Flinders Medical Centre; Envoi Pathology; Princess Alexandria Hospital; Austin Hospital; Johns Hopkins Medical Institutes; ARC-Net Centre for Applied Research on Cancer; Gönen M, Levine AJ, Allen PJ, Fearon DT, Merad M, Gnjatic S, Iacobuzio-Donahue CA, Wolchok JD, DeMatteo RP, Chan TA, Greenbaum BD, Merghoub T, Leach SD. Balachandran VP, et al. Nature. 2017 Nov 23;551(7681):512-516. doi: 10.1038/nature24462. Epub 2017 Nov 8. Nature. 2017. PMID: 29132146 Free PMC article.
Oropharyngeal Cancer Staging Health Record Extraction Using Artificial Intelligence.
Baran E, Lee M, Aviv S, Weiss J, Pettengell C, Karam I, Bayley A, Poon I, Chan KKW, Parmar A, Smoragiewicz M, Klieb H, Truong T, Maralani P, Enepekides DJ, Higgins KM, Eskander A. Baran E, et al. JAMA Otolaryngol Head Neck Surg. 2024 May 16:e241201. doi: 10.1001/jamaoto.2024.1201. Online ahead of print. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38754135
Subsequently, 4 distinct models were trained: model T (entity relationship extraction) for anatomical location and invasion state, model S (numerical extraction) for lesion size, model M (sequential classification) for metastasis detection, and a p16 model for p16 status. …
Subsequently, 4 distinct models were trained: model T (entity relationship extraction) for anatomical location and invasion state, model S ( …
Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre's Real-World Experience.
Du YJ, Fu R, Levinsky JT, Kamalraj P, Chan KKW, Parmar A, Eskander A, Smoragiewicz M. Du YJ, et al. Curr Oncol. 2023 Sep 29;30(10):8928-8935. doi: 10.3390/curroncol30100645. Curr Oncol. 2023. PMID: 37887545 Free PMC article.
A retrospective chart review was performed on patients who received nivolumab for R/M HNSCC from 2017 to 2020 at a high-volume cancer centre. Data were abstracted from 34 patients, based on physician notes and imaging reports. ...Nivolumab appears to have decreased surviva …
A retrospective chart review was performed on patients who received nivolumab for R/M HNSCC from 2017 to 2020 at a high-volume cancer …
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
Lapointe S, Mason W, MacNeil M, Harlos C, Tsang R, Sederias J, Luchman HA, Weiss S, Rossiter JP, Tu D, Seymour L, Smoragiewicz M. Lapointe S, et al. Invest New Drugs. 2020 Aug;38(4):1137-1144. doi: 10.1007/s10637-019-00875-4. Epub 2019 Nov 9. Invest New Drugs. 2020. PMID: 31707687 Clinical Trial.
Vistusertib was administered at a starting dose of 100 mg bid 2 days on/5 days off weekly with TMZ 150 mg/m(2) daily for 5 days/28-days cycle. Dose escalation was according to a 3 + 3 design. Secondary objectives included assessment of vistusertib safety and toxicity profi …
Vistusertib was administered at a starting dose of 100 mg bid 2 days on/5 days off weekly with TMZ 150 mg/m(2) daily for 5 days/28-da …
In vitro expression of the restriction endonucleases LlaMI and ScrFI isolated from Lactococcus lactis M19 and UC503.
Szatmari G, Hua NM, Vzdornov D, Daigle F, Smoragiewicz W, Mamet-Bratley MD, Karska-Wysocki B. Szatmari G, et al. J Biotechnol. 2006 Jan 24;121(2):144-53. doi: 10.1016/j.jbiotec.2005.08.004. Epub 2005 Sep 6. J Biotechnol. 2006. PMID: 16144727
Southern blotting and hybridization analysis indicate that the gene for LlaMI R/M system is chromosomally encoded....
Southern blotting and hybridization analysis indicate that the gene for LlaMI R/M system is chromosomally encoded....
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK. Kaymakcalan MD, et al. Cancer. 2016 Feb 1;122(3):411-9. doi: 10.1002/cncr.29773. Epub 2015 Nov 5. Cancer. 2016. PMID: 26540173 Free article.
In a multivariate analysis, significant predictors for TrTD were a baseline age 60 years, a glomerular filtration rate (GFR) <30 mL/min/1.73 m(2) , a single metastatic site, and a sodium level <135 mmol/L. ...
In a multivariate analysis, significant predictors for TrTD were a baseline age 60 years, a glomerular filtration rate (GFR) <30 mL/min/1 …